Effects of thalidomide combined with Camrelizumab on the incidence and efficacy of RCCEP in patients with non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060742

Enrollment

Unknown

Registered

2022-06-09

Start date

2022-06-01

Completion date

Unknown

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

reactive cutaneous capillary endothelial proliferation

Interventions

Intervention group:Thalidomide combined with carrilizhu

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with non-small cell lung cancer confirmed by histopathological and/or cytological examination; 2. There is at least one measurable lesion with a diameter greater than or equal to 20mm on conventional CT or MRI, and greater than or equal to 10mm on spiral CT; 3. Good physical condition, 0-2 in ECOG (or 60-100 in KPS); 4. The expected survival time is >= 3 months; 5. Aged > 18 years, no gender limitation; 6. Meet the chemotherapy indications and basic requirements, including normal peripheral blood imaging, no obvious abnormality of heart, liver and kidney function, normal electrocardiogram, and no unhealed trauma; 7. Informed consent signed by the patient.

Exclusion criteria

Exclusion criteria: 1) Patients whose treatment regimen includes antiangiogenic agents; 2) Existing severe acute infection, and has not been controlled, or suppurative and chronic infection, wound migration does not heal; (3) Pre-existing serious heart disease, including congestive heart failure, uncontrolled high-risk arrhythmia, unstable angina pectoris, myocardial infarction, severe valvular disease, and refractory hypertension; 4) Suffering from uncontrollable neurological, mental disease or mental disorder, poor compliance, and inability to cooperate and describe treatment response; 5) Abnormal coagulation function and bleeding tendency; Patients receiving thrombolytic or anticoagulant therapy; 6) Patients with past or current history of hemoptysis; 7) Patients with previous history of arterial thrombosis, cerebrovascular accident and gastrointestinal perforation.

Design outcomes

Primary

Measure	Time frame
Incidence of reactive cutaneous capillary endothelial proliferation;	—

Secondary

Measure	Time frame
Progression Free Survival;adverse reactions and safety;Disease Control Rate;	—

Countries

China

Contacts

Public ContactChang Jing

The Third Affiliated Hospital of Shandong First Medical University

qc419@126.com+86 13789818582

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026